Clinique Tivoli Ducos
- Address
- lock Available on a paid plan
Digestive System Diseases
Clinique Tivoli Ducos is advancing treatment for colorectal cancer and related gastrointestinal malignancies, aiming to improve survival through innovative chemotherapy and immunotherapy combinations while also exploring strategies for esophageal adenocarcinoma and gastric adenocarcinoma.
- Adjuvant chemotherapy optimization for stage II colon cancer
- Immunotherapy plus chemotherapy for microsatellite stable metastatic colorectal cancer
- Neoadjuvant approaches in locally advanced rectal cancer
- Targeted therapy for KRAS G12C‑mutated colorectal tumors
- Evaluation of intra‑operative fluorescence imaging to reduce anastomotic leaks
The research focuses on testing new therapeutic regimens, reducing treatment‑related complications, and personalizing care based on molecular markers, with the goal of extending disease‑free intervals for patients.
Female Urogenital Diseases and Pregnancy Complications
The department conducts trials on ER+/HER2‑negative metastatic breast cancer, endometrial cancer, and ovarian cancer, seeking to refine hormone‑driven therapies, evaluate de‑escalation of HER2‑targeted agents, and integrate novel targeted drugs to enhance outcomes for women.
- De‑escalation of HER2‑targeted therapy in metastatic breast cancer with ctDNA monitoring
- Adjuvant CDK4/6 inhibitor strategies for hormone‑positive early breast cancer
- Novel hormonal and immunotherapy combinations for high‑risk endometrial cancer
- PARP‑inhibitor based regimens for platinum‑resistant ovarian cancer
- Personalized adjuvant treatment decisions guided by gene‑expression profiling
These studies aim to improve disease‑free survival, reduce overtreatment, and tailor therapies to the molecular profile of each tumor, offering women more precise and effective options.
Neoplasms
Across a broad oncology portfolio, Clinique Tivoli Ducos investigates muscle‑invasive bladder cancer, triple‑negative breast cancer, and high‑risk HER2‑positive breast cancer, focusing on antibody‑drug conjugates, immune checkpoint blockade, and combination regimens to boost response rates and quality of life.
- Antibody‑drug conjugate trials in HER2‑positive breast disease
- Immunotherapy combined with chemotherapy for triple‑negative breast cancer
- Neoadjuvant checkpoint inhibition before radical cystectomy in bladder cancer
- Combination targeted agents for advanced gastric and gastro‑oesophageal junction adenocarcinoma
- Evaluation of patient‑reported outcomes and digital health tools during treatment
The overarching purpose is to assess the effectiveness of new therapeutic combinations, improve survival metrics, and enhance patient‑centred care across diverse cancer types.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 therapeutic areas and 15 of 60 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 57 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Clinique Tivoli Ducos
lock Showing 1 of 28 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| De-escalation of endocrine therapy in postmenopausal women with low-risk HR+ HER2- low Luminal A early breast cancer: a single-arm study of omission versus combination therapy | Unicancer | Phase II | Not Yet Recruiting | — | — |
IMP list
lock Showing 1 of 60 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Fluorouracil | 9 | Unknown | 2017-03-27 | 2026-05-07 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.